微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 28.03% | -50.87% | -40.21% | 118/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 46.88% | 0.45% | 8.87% | 88/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 43.06% | -9.16% | -4.45% | 90/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 45.07% | -8.31% | -21.01% | 88/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 57.05% | -8.59% | 22.25% | 59/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.67% | -31.17% | -1.54% | 87/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 47.4% | -38.16% | -3.56% | 85/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 49.15% | -40.84% | -21.25% | 83/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 62.42% | -19.75% | -7.95% | 48/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 67.81% | -14.57% | -11.53% | 43/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 76.65% | -7.12% | -7.74% | 30/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 83.07% | -0.94% | 6.81% | 18/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 77.78% | -8.65% | -2.01% | 26/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 79.38% | -5.44% | -3.82% | 27/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 82.53% | -3.33% | -1.6% | 18/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 83.87% | -1.56% | -1.5% | 18/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 85.14% | 0.67% | 1.43% | 13/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 83.94% | -2.79% | -1.67% | 16/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 85.37% | -1.3% | 0.2% | 12/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 85.2% | -1.5% | 0.74% | 10/158 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 84.57% | -1.12% | -2.06% | 11/158 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 86.35% | -1.76% | -0.16% | 10/158 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 86.49% | -1.51% | 0% | 7/158 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 86.49% | -0.71% | 1.13% | 10/158 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 85.53% | 0.04% | -2.7% | 8/158 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 87.9% | 9.84% | 0.09% | 8/158 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 87.82% | 16.65% | 0.81% | 5/158 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 87.11% | 25.01% | 1.89% | 6/158 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 85.49% | 32.32% | 6.84% | 8/158 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 80.02% | 38.77% | 6.29% | 15/158 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 75.29% | 33.59% | 8.04% | 12/158 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 69.68% | 25.07% | 7.84% | 17/158 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 64.61% | 14.14% | 12.05% | 19/158 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 57.66% | -3.93% | 2.32% | 36/158 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 56.36% | -6.65% | 1.15% | 23/158 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 55.71% | -7.7% | -1.57% | 28/158 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 56.61% | 2% | -5.69% | 21/158 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 60.02% | -1.43% | -0.58% | 28/158 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 60.37% | 2% | 0.01% | 20/158 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 60.36% | 2% | -0.86% | 22/158 | 45% | 贝达药业 | 96.95% | 行业排名> |